Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PPID | Q08752 | 3/20 | 0.43 |
| ▸ | PPIB | P23284 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | PPIG | Q13427 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11847693 | 0.95 | LMNA (0.50) | LMNACYP1A2CYP3A4MAOAALDH1A1 | |
| SCHEMBL13924144 | 0.87 | SMN1; SMN2 (0.50) | LMNAALDH1A1KDM4EHTTNPC1 | |
| SCHEMBL13557323 | 0.85 | MEN1 (0.47) | LMNACYP1A2ALDH1A1HTTTSHR | |
| SCHEMBL29697105 | 0.83 | LMNA (0.40) | LMNACYP1A2CYP3A4MAOAALDH1A1 | |
| SCHEMBL5209865 | 0.83 | ESR1 (0.53) | LMNACYP1A2CYP3A4ALDH1A1KDM4E | |
| SCHEMBL5209871 | 0.83 | ESR1 (0.53) | LMNACYP1A2CYP3A4ALDH1A1KDM4E | |
| SCHEMBL1041487 | 0.83 | LMNA (0.56) | LMNACYP1A2CYP3A4MAOAALDH1A1 | |
| SCHEMBL1625348 | 0.81 | LMNA (0.55) | LMNACYP1A2CYP3A4MAOAALDH1A1 | |
| SCHEMBL28421759 | 0.81 | OPRM1 (0.39) | LMNATSHRNPC1MEN1KMT2A | |
| SCHEMBL898279 | 0.81 | MAPT (0.47) | LMNACYP1A2ALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077076-A1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2026-03-19 | — | — | US | disclosed |
| EP-3983020-B9 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-10-16 | — | — | EP | disclosed |
| EP-4424713-A2 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | Tagworks Pharmaceuticals B.V. (NL) | 2024-09-04 | — | — | EP | disclosed |
| EP-3983020-B1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-06-26 | — | — | EP | disclosed |
| EP-4382129-A2 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | Tagworks Pharmaceuticals B.V. (NL) | 2024-06-12 | — | — | EP | disclosed |
| EP-3983363-B1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-04-10 | — | — | EP | disclosed |
| US-20240091371-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-03-21 | — | — | US | disclosed |
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-20 | — | — | US | disclosed |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-20 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| EP-1960351-B1 | PROPIONAMIDE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | HOFFMANN LA ROCHE (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-7868031-B2 | Propionamide compounds as antiinflammatory agents | ROCHE PALO ALTO LLC (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2009109998-A1 | NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS | LUPIN LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| EP-1960351-A1 | PROPIONAMIDE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065821-A1 | PROPIONAMIDE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135500-A1 | Propionamide compounds as antiinflammatory agents | ROCHE PALO ALTO LLC | 2007-06-14 | — | — | US | disclosed |
| US-20060293343-A1 | Pyrimidine derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | LMNA 4539/4885CYP1A2 291/4885CYP3A4 337/4885 |
| US-20240091371-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | LMNA 4539/4885CYP1A2 291/4885CYP3A4 337/4885 |
| US-20070135500-A1 | Propionamide compounds as antiinflammatory agents | PTGS1, PTGER1, PTGES3 | LMNA 3600/4885CYP1A2 325/4885CYP3A4 487/4885 |
| US-20060293343-A1 | Pyrimidine derivatives | PDE4A, PDE4B, PDE5A | LMNA 4490/4885CYP1A2 296/4885CYP3A4 52/4885 |
| US-20260077076-A1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | FCGR3B, MSR1, FCGR2A | LMNA 48/4885CYP1A2 3163/4885CYP3A4 3189/4885 |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | LTB4R, LTC4S, LTA4H | LMNA 3805/4885CYP1A2 2001/4885CYP3A4 465/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | LMNA 4539/4885CYP1A2 291/4885CYP3A4 337/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | LMNA 4539/4885CYP1A2 291/4885CYP3A4 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.